Peregrine Asset Advisers’s Edwards Lifesciences EW Stock Holding History

Peregrine Asset Advisers’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-3,111	Closed	-$322K	–	144
2021 Q2	$322K	Hold	3,111	–	–	0.15%	89
2021 Q1	$260K	Hold	3,111	–	–	0.13%	87
2020 Q4	$284K	Hold	3,111	–	–	0.13%	93
2020 Q3	$248K	Hold	3,111	–	–	0.14%	85
2020 Q2	$215K	Hold	3,111	–	–	0.12%	88
2020 Q1	$196K	Buy	+3,111	New	+$224K	0.15%	81
2018 Q4	–	Sell	-4,257	Closed	-$247K	–	91
2018 Q3	$247K	Hold	4,257	–	–	0.11%	107
2018 Q2	$206K	Sell	4,257 -132	-3%	-$6.16K	0.11%	110
2018 Q1	$204K	Buy	+4,389	New	+$191K	0.14%	96

Other funds holding EW

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Peregrine Asset Advisers's EW Position: Q3 2021 in Review

Peregrine Asset Advisers sold out of Edwards Lifesciences (EW) in Q3 2021, closing a stake of 3,111 shares — an estimated $322K sold.

Peregrine Asset Advisers first reported a position in EW in Q1 2018 and held it in 9 quarters. The position peaked at $322K in Q2 2021. 1,229 funds tracked by Wall St. Rank hold EW as of Q3 2021.

Peregrine Asset Advisers reported no remaining Edwards Lifesciences position as of Q3 2021 after selling out during the quarter.
Peregrine Asset Advisers sold 3,111 Edwards Lifesciences shares in Q3 2021, an estimated $322K.
Peregrine Asset Advisers first reported a position in Edwards Lifesciences in Q1 2018 and held it in 9 quarters.
Peregrine Asset Advisers's Edwards Lifesciences position peaked at $322K in Q2 2021.
1,229 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2021.

Based on Peregrine Asset Advisers's 13F filing for Q3 2021, filed 9 Nov 2021.